Endothelial Protection in Post COVID-19 Patients With Sulodexide
Post COVID-19, Endothelial Dysfunction, Thrombosis
About this trial
This is an interventional treatment trial for Post COVID-19 focused on measuring Post COVID-19, sulodexide, thrombosis, thrombomodulin
Eligibility Criteria
Inclusion Criteria:
- over 18 years old
- male or female
- Patients with documented PCR SARS-CoV-2 positive test obtained during the course of the disease
- Convalescent COVID-19 patient (define as at least 10 days after the onset of symptoms, no fever for at least 24 hours without the use of antipyretics and improvement of respiratory symptoms according to the quick COVID-19 Severity Index (qCSI).
- Signature of informed consent.
- moderate or worst clinical severity presentations of COVID-19. (According to the World Health Organization Clinical progression scale)
- Risk of health complication >50% according to the Health risk calculator
Exclusion Criteria:
- concomitant use of another anticoagulant.
- known pregnancy.
- known hypersensitivity to sulodexide
- the need for hospital care at screening
- Renal insufficiency with CrCl <30ml/min or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis.
- Blood platelet count < 30 000/µL
- Other conditions that are judged to carry an increased risk of bleeding as judged by the investigator
Elimination criteria:
A patient randomized in error (monitoring shows that in- or exclusion criteria have been violated) who never received the trial medication, will be excluded from all analyses
The investigator must discontinue study treatment for a given patient at any time for the following reasons:
• In case of intolerable serious adverse reactions/events, which are clinically relevant, suspected to be related to trial intervention, and affect the patient´s safety. This will be at the discretion of the investigator.
Sites / Locations
- Szeged University Hospital
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Centro Medico del NoroesteRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Sulodexide group
control group
the participant will receive one Sulodexide capsule of 250LRU twice a day for 8 weeks
the participant will receive on placebo capsule twice a day for 8 weeks of same appearance as IMP